| 3.1 Smoking cessation |
5 |
1447 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.94 [1.21, 3.13] |
| 3.2 Adverse events |
3 |
601 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.91, 1.11] |
| 3.2.1 1 week |
1 |
48 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.50 [0.27, 8.19] |
| 3.2.2 6 months |
1 |
298 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.71, 1.34] |
| 3.2.3 12 weeks |
1 |
255 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.94, 1.08] |
| 3.3 Serious adverse events |
6 |
1033 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.52, 1.72] |
| 3.3.1 1 week |
1 |
48 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 3.3.2 4 weeks |
1 |
74 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 3.3.3 6 months |
3 |
794 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.52, 1.72] |
| 3.3.4 1 year |
1 |
117 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 3.4 Carbon monoxide (ppm) |
3 |
320 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.88 [‐2.67, ‐1.09] |
| 3.4.1 2 weeks |
1 |
25 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐3.00, 2.20] |
| 3.4.2 12 weeks |
1 |
146 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.40 [‐5.18, ‐1.62] |
| 3.4.3 6 months |
1 |
149 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.65 [‐2.59, ‐0.71] |
| 3.5 Heart rate |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.5.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.6 Systolic blood pressure |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.6.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.7 FeNO (ppb) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.7.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.8 FEV1 (l) |
1 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.8.1 12 weeks |
1 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.9 FVC (l) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.9.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.10 FEV1/FVC |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.10.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.11 NNAL (pg/mg creatinine) at 24 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.12 Product use at 6+ months |
2 |
399 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.91, 1.54] |
